INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2014年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页码：E144 / E145
页数：2
相关论文
共 50 条
  • [11] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
    Siegel, D.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lenial, S.
    ONKOLOGIE, 2013, 36 : 39 - 40
  • [12] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
    Siegel, D. S.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lonial, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 20 - 20
  • [13] Single-agent Aredia for relapsed/refractory multiple myeloma.
    Berenson, JR
    Webb, IJ
    Anderson, K
    Schlossman, R
    Vescio, R
    Doss, D
    Goon, B
    Swift, R
    VonTeichert, J
    Kowalski, M
    Seaman, J
    BLOOD, 1999, 94 (10) : 307B - 307B
  • [14] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (04) : 772 - 778
  • [15] HEMATOLOGIC SAFETY PROFILE OF SINGLE-AGENT CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA FROM FOUR PHASE 2 STUDIES
    Nooka, A.
    HAEMATOLOGICA, 2012, 97 : 601 - 601
  • [16] Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib
    Jakubowiak, Andrzej J.
    Martin, Thomas
    Singhal, Seema B.
    Wang, Michael
    Vij, Ravi
    Jagannath, Sundar
    Lonial, Sagar
    Kukreti, Vishal
    Buadi, Francis
    Bray, Lauren
    Vallone, Marcy
    Kauffman, Michael
    Orlowski, Robert Z.
    Siegel, David Samuel diCapua
    BLOOD, 2010, 116 (21) : 809 - 809
  • [17] Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
    Siegel, David S.
    Martin, Thomas
    Wang, Michael
    Vij, Ravi
    Jakubowiak, Andrzej J.
    Lonial, Sagar
    Trudel, Suzanne
    Kukreti, Vishal
    Bahlis, Nizar
    Alsina, Melissa
    Chanan-Khan, Asher
    Buadi, Francis
    Reu, Frederic J.
    Somlo, George
    Zonder, Jeffrey
    Song, Kevin
    Stewart, A. Keith
    Stadtmauer, Edward
    Kunkel, Lori
    Wear, Sandra
    Wong, Alvin F.
    Orlowski, Robert Z.
    Jagannath, Sundar
    BLOOD, 2012, 120 (14) : 2817 - 2825
  • [18] RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM)
    Jakubowiak, A. J.
    Martin, T.
    Singhal, S.
    Wang, M.
    Vij, R.
    Jagannath, S.
    Lonial, S.
    Kukreti, V.
    Buadi, F.
    Kunkel, L.
    Bray, L.
    Vallone, M.
    Orlowski, R. Z.
    Siegel, D. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 122 - 122
  • [19] A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE
    Jonsson, F.
    Siegel, D.
    Jagannath, S.
    Vij, R.
    Badros, A.
    Ou, Y.
    Claret, L.
    Kavalerchik, E.
    Bruno, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S75 - S75
  • [20] Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
    Harvey, R. Donald
    Lonial, Sagar
    Patel, Priti
    McCulloch, Leanne
    Niesvizky, Ruben
    Kaufman, Jonathan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345